logo
Plus   Neg
Share
Email

Bristol-Myers Squibb Reports Phase 3 CheckMate -227 Trial Results - Quick Facts

Bristol-Myers Squibb Company (BMY) said Part 1a of the Phase 3 CheckMate -227 trial evaluating Opdivo plus low-dose Yervoy met the co-primary endpoint of overall survival, demonstrating a superior benefit versus chemotherapy in first-line non-small cell lung cancer patients whose tumors express PD-L1 =1%. In an exploratory analysis of patients in Part 1b whose tumors do not express PD-L1, a survival benefit was also observed with Opdivo plus low-dose Yervoy.

However, part 2 of the CheckMate -227 trial, evaluating Opdivo plus chemotherapy, did not meet the pre-specified primary endpoint of overall survival versus chemotherapy in patients with non-squamous histology, regardless of PD-L1 status.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Video streaming giant Netflix said it will donate 1 million euros to Audiens, the social protection group of the French cultural sector, to help launch a COVID-19 emergency relief fund to support workers in the French television and cinema industry. Netflix and Audiens said they have created the new COVID-19 Film and TV Emergency Relief Fund to help the hardest hit workers in the industry. Major U.S. retail container ports are estimated to report a five-year low for imports in March as consumer demand has been impacted with millions of Americans out of work amid the coronavirus (COVID-19) outbreak, according to a report by the National Retail Federation or NRF. The U.S. Food and Drug Administration has issued warning letters to three sellers of fraudulent COVID-19 products. There are currently no approved preventatives or treatments for COVID-19, the FDA said in a statement.
Follow RTT
>